Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease

Bibliography

• Citron M. Alzheimer's disease: treatments in discovery and development. Nat Neurosci 2002;(Suppl 5):1055-57
   PubMed Web of Science ®Google Scholar
• Samuels SC, Davis KL. Dementia and delirium. In: Enna SJ, Coyle JT, editors, Pharmacological management of neurological and psychiatric disorders. New York, McGraw Hill; 1998. p. 267-316
   Google Scholar
• Brendza RP, Bacskai BJ, Cirrito JR, et al. Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 2005;115:428-33
   PubMed Web of Science ®Google Scholar
• Hartman RE, Izumi Y, Bales KR, et al. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci 2005;25:6213-20
   PubMed Web of Science ®Google Scholar
• Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002;41:345-52
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004;11:213-28
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44:181-93
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999;399:A23-31
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003;61:46-54
   PubMed Web of Science ®Google Scholar
• Terry RD. Neuropathological changes in Alzheimer disease. Prog Brain Res 1994;101:383-90
   PubMed Web of Science ®Google Scholar
• Trojanowski JQ, Clark CM, Schmidt ML, et al. Strategies for improving the postmortem neuropathological diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18:S75-9
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006;12:1005-15
   PubMed Web of Science ®Google Scholar
• Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-21
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6
   PubMed Web of Science ®Google Scholar
• Rowan MJ, Klyubin I, Wang Q, Anwyl R. Mechanisms of the inhibitory effects of amyloid β-protein on synaptic plasticity. Exp Gerontol 2004;39:1661-7
   PubMed Web of Science ®Google Scholar
• Li R, Yang L, Lindholm K, et al. Tumor necrosis factor death receptor signaling cascade is required for amyloid-β protein-induced neuron death. J Neurosci 2004;24:1760-71
   PubMed Web of Science ®Google Scholar
• Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-α. Nature 2006;440:1054-9
   PubMed Web of Science ®Google Scholar
• Albensi BC, Mattson MP. Evidence for the involvement of TNF and NF-κB in hippocampal synaptic plasticity. Synapse 2000;35:151-9
   PubMed Web of Science ®Google Scholar
• Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 2007;8:101-12
   PubMed Web of Science ®Google Scholar
• Klyubin I, Walsh DM, Lemere CA, et al. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005;11:556-61
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. The ups and downs of Aβ. Nat Med 2006;12:758-9; discussion 759
   PubMed Web of Science ®Google Scholar
• Tanzi RE. The synaptic Aβ hypothesis of Alzheimer disease. Nat Neurosci 2005;8:977-9
   PubMed Web of Science ®Google Scholar
• Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid β induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 2006;26:6011-8
   PubMed Web of Science ®Google Scholar
• Lacor PN, Buniel MC, Furlow PW, et al. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007;27:796-807
   PubMed Web of Science ®Google Scholar
• Lanz TA, Carter DB, Merchant KM. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis 2003;13:246-53
   PubMed Web of Science ®Google Scholar
• Jacobsen JS, Wu CC, Redwine JM, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:5161-6
   PubMed Web of Science ®Google Scholar
• Oddo S, Vasilevko V, Caccamo A, et al. Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 2006;281:39413-23
   PubMed Web of Science ®Google Scholar
• Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 2005;8:79-84
   PubMed Web of Science ®Google Scholar
• Oddo S, Caccamo A, Tran L, et al. Temporal profile of amyloid-beta (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J Biol Chem 2006;281:1599-604
   PubMed Web of Science ®Google Scholar
• Calabrese B, Halpain S. Essential role for the PKC target MARCKS in maintaining dendritic spine morphology. Neuron 2005;48:77-90
   PubMed Web of Science ®Google Scholar
• Calabrese B, Shaked GM, Tabarean IV, et al. Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-β protein. Mol Cell Neurosci 2007;35:183-93
   PubMed Web of Science ®Google Scholar
• Britschgi M, Wyss-Coray T. Systemic and acquired immune responses in Alzheimer's disease. Int Rev Neurobiol 2007;82:205-33
   PubMed Web of Science ®Google Scholar
• Ethell DW, Shippy D, Cao C, et al. Aβ-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis 2006;23:351-61
   PubMed Web of Science ®Google Scholar
• Das P, Murphy MP, Younkin LH, et al. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 2001;22:721-7
   PubMed Web of Science ®Google Scholar
• Gandy S, DeMattos RB, Lemere CA, et al. Alzheimer's Aβ vaccination of rhesus monkeys (Macaca mulatta). Alzheimer Dis Assoc Disord 2004;18:44-6
   PubMed Web of Science ®Google Scholar
• Lemere CA, Beierschmitt A, Iglesias M, et al. Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004;165:283-97
   PubMed Web of Science ®Google Scholar
• Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003;100:2023-8
   PubMed Web of Science ®Google Scholar
• Solomon B. Active immunization against Alzheimer's β-amyloid peptide using phage display technology. Vaccine 2007;25:3053-6
   PubMed Web of Science ®Google Scholar
• Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J Biol Chem 2006;281:4292-9
   PubMed Web of Science ®Google Scholar
• Gardberg AS, Dice LT, Ou S, et al. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci USA 2007;104:15659-64
   PubMed Web of Science ®Google Scholar
• Banks WA, Pagliari P, Nakaoke R, Morley JE. Effects of a behaviorally active antibody on the brain uptake and clearance of amyloid beta proteins. Peptides 2005;26:287-94
   PubMed Web of Science ®Google Scholar
• Banks WA, Terrell B, Farr SA, et al. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 2002;23:2223-6
   PubMed Web of Science ®Google Scholar
• Kozlowski GP, Sterzl I, Nilaver G. Localization patterns for immunoglobulins and albumins in the brain suggest diverse mechanisms for their transport across the blood-brain barrier (BBB). Prog Brain Res 1992;91:149-54
   PubMed Web of Science ®Google Scholar
• Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci USA 1994;91:5705-9
   PubMed Web of Science ®Google Scholar
• Poduslo JF, Ramakrishnan M, Holasek SS, et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem 2007;102:420-33
   PubMed Web of Science ®Google Scholar
• Billings LM, Oddo S, Green KN, et al. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005;45:675-88
   PubMed Web of Science ®Google Scholar
• Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001;7:369-72
   PubMed Web of Science ®Google Scholar
• Chauhan NB, Siegel GJ. Reversal of amyloid β toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid β antibody. J Neurosci Res 2002;69:10-23
   PubMed Web of Science ®Google Scholar
• Chauhan NB, Siegel GJ. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease. Expert Rev Vaccines 2004;3:717-25
   PubMedGoogle Scholar
• Tampellini D, Magrane J, Takahashi RH, et al. Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations. J Biol Chem 2007;282:18895-906
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-9
   PubMed Web of Science ®Google Scholar
• Das P, Howard V, Loosbrock N, et al. Amyloid-β immunization effectively reduces amyloid deposition in FcRγ-/- knock-out mice. J Neurosci 2003;23:8532-8
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-5
   PubMed Web of Science ®Google Scholar
• Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 1996;93:452-5
   PubMed Web of Science ®Google Scholar
• Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997;94:4109-12
   PubMed Web of Science ®Google Scholar
• Solomon B. Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease. DNA Cell Biol 2001;20:697-703
   PubMed Web of Science ®Google Scholar
• Lemere CA, Spooner ET, LaFrancois J, et al. Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice. Neurobiol Dis 2003;14:10-8
   PubMed Web of Science ®Google Scholar
• Solomon B. Alzheimer's disease and immunotherapy. Curr Alzheimer Res 2004;1:149-63
   PubMed Web of Science ®Google Scholar
• Hock C, Konietzko U, Streffer JR, et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-554
   PubMed Web of Science ®Google Scholar
• Masliah E, Hansen L, Adame A, et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005;64:129-31
   PubMed Web of Science ®Google Scholar
• Lee M, Bard F, Johnson-Wood K, et al. Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies. Ann Neurol 2005;58:430-5
   PubMed Web of Science ®Google Scholar
• Schenk D. Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002;3:824-8
   PubMed Web of Science ®Google Scholar
• Agadjanyan MG, Ghochikyan A, Petrushina I, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005;174:1580-6
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. J Immunol 2005;174:2453-5
   PubMed Web of Science ®Google Scholar
• Clark M. Antibody humanization: a case of the ‘Emperor's new clothes’? Immunol Today 2000;21:397-402
   PubMedGoogle Scholar
• Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000;355:735-40
   PubMed Web of Science ®Google Scholar
• Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003;2:52-62
   PubMed Web of Science ®Google Scholar
• Steinitz M. Human monoclonal antibodies produced by EBV immortalized cell lines: technical and theoretical principles. In: Pal RS, editor, Immunoassay technology. Macmillan Press, UK; 1988. p. 1-7
   Google Scholar
• Foulkes R. Preclinical safety evaluation of monoclonal antibodies. Toxicology 2002;174:21-6
   PubMed Web of Science ®Google Scholar
• Lynch CM, Grewal IS. Preclinical safety evaluation of monoclonal antibodies. Handb Exp Pharmacol 2008:19-44
   PubMedGoogle Scholar
• Lemere CA, Maier M, Jiang L, et al. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res 2006;9:77-84
   PubMed Web of Science ®Google Scholar
• Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002;22:6331-5
   PubMed Web of Science ®Google Scholar
• Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-7
   PubMed Web of Science ®Google Scholar
• Rakover I, Arbel M, Solomon B. Immunotherapy against APP β-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain Aβ levels. Neurodegener Dis 2007;4:392-402
   PubMed Web of Science ®Google Scholar
• Nath A, Hall E, Tuzova M, et al. Autoantibodies to amyloidβ-peptide (Aβ) are increased in Alzheimer's disease patients and Aβ antibodies can enhance Aβ neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med 2003;3:29-39
   PubMed Web of Science ®Google Scholar
• Hyman BT, Smith C, Buldyrev I, et al. Autoantibodies to amyloid-β and Alzheimer's disease. Ann Neurol 2001;49:808-10
   PubMed Web of Science ®Google Scholar
• Rowan MJ, Klyubin I, Wang Q, et al. Synaptic memory mechanisms: Alzheimer's disease amyloid β-peptide-induced dysfunction. Biochem Soc Trans 2007;35:1219-23
   PubMed Web of Science ®Google Scholar
• Moir RD, Tseitlin KA, Soscia S, et al. Autoantibodies to redox-modified oligomeric Aβ are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 2005;280:17458-63
   PubMed Web of Science ®Google Scholar
• Powers JM, Schlaepfer WW, Willingham MC, Hall BJ. An immunoperoxidase study of senile cerebral amyloidosis with pathogenetic considerations. J Neuropathol Exp Neurol 1981;40:592-612
   PubMed Web of Science ®Google Scholar
• Munoz DG, Erkinjuntti T, Gaytan-Garcia S, Hachinski V. Serum protein leakage in Alzheimer's disease revisited. Ann NY Acad Sci 1997;826:173-89
   PubMed Web of Science ®Google Scholar
• Galili U, Kobrin E, Macher BA, Shohet SB. Anti-Gal and human red cell aging. Prog Clin Biol Res 1989;319:225-41; discussion 242-225
   PubMedGoogle Scholar
• Duquerroy S, Stura EA, Bressanelli S, et al. Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. J Mol Biol 2007;368:1321-31
   PubMed Web of Science ®Google Scholar
• Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-57
   PubMed Web of Science ®Google Scholar
• Bouras C, Riederer BM, Kovari E, et al. Humoral immunity in brain aging and Alzheimer's disease. Brain Res Brain Res Rev 2005;48:477-87
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Buciak JL, Friden PM. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther 1991;259:66-70
   PubMed Web of Science ®Google Scholar
• Vrethem M, Henriksson A, Malm C, et al. Ig-secreting cells pass the blood-brain barrier: studies on kappa and lambda light chain secreting cells in plasma cell dyscrasia. J Neuroimmunol 1992;41:189-94
   PubMed Web of Science ®Google Scholar
• Gold G, Giannakopoulos P, Bouras C. Re-evaluating the role of vascular changes in the differential diagnosis of Alzheimer's disease and vascular dementia. Eur Neurol 1998;40:121-9
   PubMed Web of Science ®Google Scholar
• Banks WA, Farr SA, Morley JE, et al. Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment. Exp Neurol 2007;206:248-56
   PubMed Web of Science ®Google Scholar
• Elan: Elan and Wyeth Research in Amyloid immunotherapy:humanized anti-amyloid beta AAB-001 2007. Available from : http://www.elan.com/research_development/Alzheimers [Last accessed 8 March 2008]
   Google Scholar
• Steinitz M, Klein E. Human monoclonal antibodies produced by immortalization of antien binding B cells with Epstein-Barr Virus (EBV). Immunol Today 1981;2:38-9
   PubMedGoogle Scholar
• Steinitz M, Izak G, Cohen S, et al. Continuous production of monoclonal rheumatoid factor by EBV-transformed lymphocytes. Nature 1980;287:443-5
   PubMed Web of Science ®Google Scholar
• Xu S, Gaskin F. Increased incidence of anti-β-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech Ageing Dev 1997;94:213-22
   PubMed Web of Science ®Google Scholar
• Geylis V, Kourilov V, Meiner Z, et al. Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 2005;26:597-606
   PubMed Web of Science ®Google Scholar
• Shannon-Lowe C, Baldwin G, Feederle R, et al. Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth. J Gen Virol 2005;86:3009-19
   PubMed Web of Science ®Google Scholar
• Traggiai E, Becker S, Subbarao K, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004;10:871-5
   PubMed Web of Science ®Google Scholar
• Geylis V, Steinitz M. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Aβ) human monoclonal antibodies. Autoimmun Rev 2006;5:33-9
   PubMed Web of Science ®Google Scholar
• Blank M, Nur I, Toub O, et al. Toward molecular targeting with specific intravenous immunoglobulin preparation. Clin Rev Allergy Immunol 2005;29:213-7
   PubMed Web of Science ®Google Scholar
• Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1472-4
   PubMed Web of Science ®Google Scholar
• Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2008; Epub ahead of print
   PubMedGoogle Scholar
• Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-β peptide. J Neurosci Res 2006;84:434-43
   PubMed Web of Science ®Google Scholar
• Lister RK, Jolles S, Whittaker S, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 2000;43:403-8
   PubMed Web of Science ®Google Scholar
• Berger JR, Dobbs MR, Terhune MH, Maragos WF. The neurologic complications of scleromyxedema. Medicine (Baltimore) 2001;80:313-9
   PubMed Web of Science ®Google Scholar
• Shergill B, Orteu CH, McBride SR, Rustin MH. Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin. Br J Dermatol 2005;153:650-52
   PubMed Web of Science ®Google Scholar